LAUSR

DAA: direct-acting antiviral HCV: hepatitis C virus LP: lichen planus SVR: sustained viral response UCSF: University of California, San Francisco H epatitis C virus (HCV) infection is associated with many extrahepatic manifestations, including skin diseases such as lichen planus (LP). New direct-acting antiviral (DAA) agents are highly effective in treating HCV, and many extrahepatic manifestations of HCV improve after treatment. However, limited data exist regarding outcomes of HCV-associated skin disease after DAA treatment. Case reports and series have documented HCV-associated cryoglobulinemic vasculitis, porphyria cutanea tarda, and oral and cutaneous LP improving or resolving after DAA treatment. Conversely, new-onset LP developing 3 months after HCV treatment with elbasvir-grazoprevir was recently described, and a patient with pre-existing oral LP who had new cutaneous LP after treatment with ledipasvir-sofosbuvir was also reported. We present 3 patients in whomnew LP developedwithin months after treatment of HCV with DAA. With these cases, we highlight the need to further understand the connection between HCV and LP.